Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Medicina (Kaunas) ; 58(8)2022 Aug 19.
Artigo em Inglês | MEDLINE | ID: mdl-36013592

RESUMO

Background and Objectives: Particulate Matter (PM), particles of variable but small diameter can penetrate the respiratory system via inhalation, causing respiratory and/or cardiovascular diseases. This study aims to evaluate the association of environmental particulate matter (PM2.5) and black carbon (BC) with respiratory health in users of different transport modes in four roads in Bogotá. Materials and Methods: this was a mixed-method study (including a cross sectional study and a qualitative description of the air quality perception), in 300 healthy participants, based on an exploratory sequential design. The respiratory effect was measured comparing the changes between pre- and post-spirometry. The PM2.5 and black carbon (BC) concentrations were measured using portable devices. Inhaled doses were also calculated for each participant according to the mode and route. Perception was approached through semi-structured interviews. The analysis included multivariate models and concurrent triangulation. Results: The concentration of matter and black carbon were greater in bus users (median 50.67 µg m-3; interquartile range (-IR): 306.7). We found greater inhaled dosages of air pollutants among bike users (16.41 µg m-3). We did not find changes in the spirometry parameter associated with air pollutants or transport modes. The participants reported a major sensory influence at the visual and olfactory level as perception of bad air quality. Conclusions: We observed greater inhaled doses among active transport users. Nevertheless, no pathological changes were identified in the spirometry parameters. People's perceptions are a preponderant element in the assessment of air quality.


Assuntos
Poluentes Atmosféricos , Poluição do Ar , Poluentes Atmosféricos/análise , Poluição do Ar/efeitos adversos , Carbono , Colômbia , Estudos Transversais , Exposição Ambiental/efeitos adversos , Humanos , Material Particulado/efeitos adversos
2.
Future Oncol ; 17(17): 2127-2140, 2021 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-33709777

RESUMO

Epigenetic alterations are major drivers of follicular lymphomagenesis, and these alterations are frequently caused by mutations in or upregulation of EZH2, a histone methyltransferase responsible for PRC2-mediated gene repression. EZH2 hyperactivation increases proliferation of B cells and prevents them from exiting the germinal center, favoring lymphomagenesis. The first FDA-approved EZH2 inhibitor is tazemetostat, which is orally available and targets both mutant and wild-type forms of the protein to induce cell cycle arrest and apoptosis of lymphoma cells in preclinical models. Phase II trials have shown objective response rates of 69% for patients with lymphoma-carrying EZH2 mutations and 35% for those with wild-type EZH2 without major toxicity, leading to tazemetostat approval for this cancer by the US FDA in June 2020.


Lay abstract Follicular lymphoma (FL) is a subtype of B-cell cancer. Initial prognosis of this disease is favorable as first-line treatments provide responses lasting 10 years on average. However, most patients will experience relapse and subsequent treatments are not as efficient nor as well tolerated as the first ones. An important driver of FL is a gene called EZH2 that makes B cells proliferate, either because of mutations that increase its activity or because of a net increase in its concentration in lymphoma cells. Tazemetostat is a drug that was designed to inhibit EZH2 protein and thus lymphoma cell growth. Phase I and II studies have been completed for this drug showing a good safety profile. In Phase II, reponses were seen in 69% of patients who have the EZH2 mutations and 35% of the other patients. The US FDA has approved tazemetostat for patients with FL who have had at least two previous treatments and harbor the EZH2 mutations, or for patients with FL who have no other therapeutic options. However, the drug has not yet been approved in Europe. Randomized trials and long-term follow-up will be of interest to make sure this drug is efficient and safe enough to be given to patients in earlier lines of treatment or in combination with other active agents used to treat patients with FL.


Assuntos
Benzamidas/uso terapêutico , Compostos de Bifenilo/uso terapêutico , Resistencia a Medicamentos Antineoplásicos/efeitos dos fármacos , Proteína Potenciadora do Homólogo 2 de Zeste/antagonistas & inibidores , Linfoma Folicular/tratamento farmacológico , Morfolinas/uso terapêutico , Mutação , Recidiva Local de Neoplasia/tratamento farmacológico , Piridonas/uso terapêutico , Terapia de Salvação , Ensaios Clínicos Fase I como Assunto , Ensaios Clínicos Fase II como Assunto , Avaliação Pré-Clínica de Medicamentos , Proteína Potenciadora do Homólogo 2 de Zeste/genética , Humanos , Linfoma Folicular/genética , Linfoma Folicular/patologia , Dose Máxima Tolerável , Recidiva Local de Neoplasia/genética , Recidiva Local de Neoplasia/patologia , Prognóstico , Taxa de Sobrevida
3.
J Clin Invest ; 131(13)2021 07 01.
Artigo em Inglês | MEDLINE | ID: mdl-34043588

RESUMO

Peripheral T cell lymphomas (PTCLs) represent a significant unmet medical need with dismal clinical outcomes. The T cell receptor (TCR) is emerging as a key driver of T lymphocyte transformation. However, the role of chronic TCR activation in lymphomagenesis and in lymphoma cell survival is still poorly understood. Using a mouse model, we report that chronic TCR stimulation drove T cell lymphomagenesis, whereas TCR signaling did not contribute to PTCL survival. The combination of kinome, transcriptome, and epigenome analyses of mouse PTCLs revealed a NK cell-like reprogramming of PTCL cells with expression of NK receptors (NKRs) and downstream signaling molecules such as Tyrobp and SYK. Activating NKRs were functional in PTCLs and dependent on SYK activity. In vivo blockade of NKR signaling prolonged mouse survival, demonstrating the addiction of PTCLs to NKRs and downstream SYK/mTOR activity for their survival. We studied a large collection of human primary samples and identified several PTCLs recapitulating the phenotype described in this model by their expression of SYK and the NKR, suggesting a similar mechanism of lymphomagenesis and establishing a rationale for clinical studies targeting such molecules.


Assuntos
Linfoma de Células T Periférico/imunologia , Receptores de Antígenos de Linfócitos T/imunologia , Receptores de Células Matadoras Naturais/imunologia , Animais , Carcinogênese/genética , Carcinogênese/imunologia , Reprogramação Celular/genética , Reprogramação Celular/imunologia , Epigênese Genética , Regulação Neoplásica da Expressão Gênica , Genes p53 , Humanos , Células Matadoras Naturais/imunologia , Linfoma de Células T Periférico/genética , Linfoma de Células T Periférico/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Neoplasias Experimentais/genética , Neoplasias Experimentais/imunologia , Neoplasias Experimentais/metabolismo , Receptores de Antígenos de Linfócitos T/genética , Receptores de Células Matadoras Naturais/genética , Transdução de Sinais/genética , Transdução de Sinais/imunologia , Quinase Syk/metabolismo , Linfócitos T/imunologia
6.
Cambios rev. méd ; 21(1): 798, 30 Junio 2022. tabs, grafs.
Artigo em Espanhol | LILACS | ID: biblio-1400361

RESUMO

INTRODUCCIÓN. La hemofilia es una condición rara hereditaria, crónica, potencialmente discapacitante e incapacitante, caracterizada por frecuentes sangrados debidos al déficit del factor VIII coagulante, Hemofilia A o del factor IX Hemofilia B. Las evaluaciones de calidad de vida en personas con hemofilia, basadas principalmente en el aspecto biológico, llevaron a considerar un importante enfoque bioético que evalúe la afectación de la autonomía y dignidad debida a la enfermedad. OBJETIVO. Registrar la percepción de la autonomía y dignidad de personas que viven con hemofilia. MATERIALES Y MÉTODOS. Estudio descriptivo transversal. Población de 92 y muestra de 28 varones mayores de 18 años con diagnóstico de hemofilia, atendidos en la Clínica de Coagulopatías Congénitas del Hospital de Especialidades Carlos Andrade Marín en el periodo marzo 2021 a agosto del 2021. Se excluyó a varones menores de 18 años atendidos en otras instituciones del Sistema Nacional de Salud. Estudio basado en el desarrollo de las capacidades centrales descritas por Martha Nussbaum. Se aplicó el test The Hemophilia Well Being Index que evaluó calidad de vida con relación al bienestar personal asociado a salud, y la herramienta Body Mapping que analizó en base al interpretativismo fenomenológico. RESULTADOS. El 100% de personas presentaron afectación en algún área de la vida investigada por el Hemophilia Well Being Index, que se confirma con las expresiones escritas y gráficas recopiladas por el Body Mapping. CONCLUSIÓN. La autonomía y dignidad se encuentran afectadas en las personas que viven con hemofilia, al igual que las capacidades centrales; es importante valorar cómo estos parámetros afectan la consecución de logros, lo que se debe considerar en estudios futuros.


INTRODUCTION. Hemophilia is a rare hereditary, chronic, potentially disabling and incapacitating condition, characterized by frequent bleeds due to deficiency of clotting factor VIII, Hemophilia A or factor IX Hemophilia B. Quality of life assessments in people with hemophilia, mainly based on the biological aspect, led to consider an important bioethical approach that evaluates the impairment of autonomy and dignity due to the disease. OBJECTIVE. To record the perception of autonomy and dignity of people living with hemophilia. MATERIALS AND METHODS. Cross-sectional descriptive study. Population of 92 and sample of 28 males over 18 years of age with a diagnosis of hemophilia, attended at the Congenital Coagulopathy Clinic of the Carlos Andrade Marin Specialty Hospital in the period March 2021 to August 2021. Males under 18 years of age attended in other institutions of the National Health System were excluded. The study was based on the development of the central capabilities described by Martha Nussbaum. The test The Hemophilia Well Being Index was applied, which evaluated quality of life in relation to personal wellbeing associated with health, and the tool Body Mapping which analyzed based on phenomenological interpretivism. RESULTS. 100% of people presented affectation in some area of life investigated by the Hemophilia Well Being Index, which is confirmed by the written and graphic expressions collected by the Body Mapping. CONCLUSION. Autonomy and dignity are affected in people living with hemophilia, as are core capacities; it is important to assess how these parameters affect achievement, which should be considered in future studies.


Assuntos
Humanos , Masculino , Adolescente , Adulto , Pessoa de Meia-Idade , Idoso , Adulto Jovem , Percepção , Qualidade de Vida , Hemofilia B , Autonomia Pessoal , Assistência ao Paciente , Hemofilia A , Coagulação Sanguínea , Fatores de Coagulação Sanguínea , Fator IX , Fator XIII , Doença Crônica , Direitos Civis , Indicadores de Doenças Crônicas
7.
Cambios rev. méd ; 19(1): 110-120, 30/06/2020. tab, ilus
Artigo em Espanhol | LILACS | ID: biblio-1122667

RESUMO

Las enfermedades infecciosas emergentes y reemergentes son desafíos constantes para la salud pública en todo el mundo. Los casos recientes de neumonía de causa desconocida en Wuhan, China, han llevado al descubrimiento de un nuevo tipo de Coronavirus (2019-nCoV), que son virus de Ácido Ribonucleico (RNA) envueltos, de forma común encontrados en humanos, otros mamíferos y aves, capaces de causar enfermedades respiratorias, entéricas, hepáticas y neurológicas 1. La amenaza a la salud de la infección por Coronavirus 2 asociado al SRAS (SARS-CoV-2) y la enfermedad que produce el mismo llamada Enfermedad por Coronavirus (COVID-19) ya está estable- cida con sus tasas de infección y mortalidad de manera considerable más altas si se lo compara con otros virus respiratorios adquiridos en la comunidad 2. En tal sentido es necesario dar una respuesta por parte de la Unidad Técnica de Hematología en relación a esta pandemia con el ánimo de aportar al manejo integral de estos pacientes, homogeneizar criterios clínicos, lidiar de mejor manera con la incertidumbre en el diagnóstico y tratamiento de COVID-19. El SARS CoV-2 y su enfermedad COVID-19, en la mayoría de pacientes tiene una presentación con síntomas leves. Sin embargo, en el 5% de los casos diagnosticados requerirán de una Unidad de Cuidados Intensivos (UCI)3, ya que presentan Síndrome de Dificultad Respiratoria Aguda (SDRA), shock séptico, Insuficiencia Multiorgánica y coagulopatía hemorrágica, así como trombótica, incluyendo Coagulación Intravascular Diseminada (CID), alcanzado en las salas de UCI una tasa mortalidad por COVID-19 entre el 22% al 62% en algunas series 4. Adicional, se ha observado que el grupo de pacientes con mala evolución presentan un estado hiperinflamatorio, asemejándose al cuadro clínico descrito de una linfohistiocitosis hemofagocítica secundaria, que en este caso sería desencadenada por SARS CoV-2 5. Un grupo de Hematólogos de diferentes hospitales de la ciudad de Quito: Especialidades Carlos Andrade Marín-Instituto Ecuatoriano de Seguridad Social (HECAM-IESS), Metropolitano; y, hospitales de la ciudad de Guayaquil: Teodoro Maldonado Carbo-IESS, Hospital Luis Vernaza y Clínica Gilbert, basados en la evidencia científica disponible y experticia profesional, elaboraron éste protocolo con las recomendaciones según los diferentes escenarios y complicaciones hematológicas.


Emerging and reemerging infectious diseases are constant challenges to public health worldwide. Recent cases of pneumonia of unknown cause in Wuhan, China have led to the discovery of a new type of Coronavirus (2019-nCoV), which are enveloped ribonucleic acid (RNA) viruses, commonly found in humans, other mammals, and birds, capable of cause respiratory, enteric, liver and neurological diseases 1. The health threat of SARS-associated coronavirus 2 (SARS-CoV-2) and the disease that produces it called COVID-19 has already been established with its considerably higher infection and mortality rates compared to other respiratory viruses acquired in the community 2. In this sense, it is necessary to give a response from the Hematology Technical Unit in relation to this pandemic in order to contribute to the comprehensive management of these patients, homogenize clinical criteria, better deal with uncertainty in the diagnosis and treatment of COVID-19. SARS CoV-2 and its disease COVID-19, in the majority of patients have a presentation with mild symptoms. However, in 5% of diagnosed cases they will require an Intensive Care Unit (ICU) 3, since they present Acute Respiratory Distress Syndrome (ARDS), septic shock, Multiple Organ Failure and hemorrhagic coagulopathy, as well as thrombotic, including Coagulation Disseminated Intravascular (DIC), achieved in the ICU wards a mortality rate for COVID-19 between 22% and 62% in some series 4. Additionally, it has been observed that the group of patients with poor evolution present a hyperinflammatory state, resembling the clinical picture of secondary hemopha- gocytic lymphohistiocytosis, which in this case would be triggered by SARS CoV-2 5. The group of Hematologists from the hospitals of the city of Quito: Specialties Carlos Andrade Marín HECAM-IESS, Metropolitano; and, hospitals in the city of Guayaquil: Teodoro Maldonado Carbo-IESS, Luis Vernaza Hospital and Gilbert Clinic, based on the available scientific evidence and professional expertise, prepared this protocol with the recommendations according to the different hematological scenarios and complications.


Assuntos
Humanos , Masculino , Feminino , Plasma , Pneumonia , RNA Viral , Infecções por Coronavirus , Coronavírus Relacionado à Síndrome Respiratória Aguda Grave , Anticoagulantes , Coagulação Sanguínea , Mortalidade , Síndrome Respiratória Aguda Grave , Pandemias , Betacoronavirus , Mamíferos
8.
Cambios rev. méd ; 19(1): 97-109, 30/06/2020. ilus.
Artigo em Espanhol | LILACS | ID: biblio-1122716

RESUMO

El 30 de enero de 2020, la Organización Mundial de la Salud (OMS) declara que el brote de Enfermedad por Coronavirus (COVID-19) constituye una Emergencia Sanitaria de Salud de Preocupación Internacional/Public Health Emergencies of International Concern (PHEIC). El 11 de marzo de 2020, la OMS declara la pandemia1,2. El COVID-19 es una enfermedad respiratoria aguda causada por un coronavirus zoonótico de reciente aparición1. Los coronavirus son una familia de virus que se descubrió en la década de los 60 pero cuyo origen es todavía desconocido. Pueden causar enfermedades tanto en animales como en humanos. En los humanos se sabe que varios coronavirus (229E, OC43, NL63 y HUK 1) son responsables del resfriado común y en raras ocasiones se pueden producir infecciones graves de las vías respiratorias inferiores. Dos de los coronavirus causan infecciones en los seres humanos muchos más graves e incluso a veces mortales; estos son: el Coronavirus del Síndrome Respiratorio de Oriente Medio (MERS-CoV), y el Coronavirus tipo 2 asociado al SARS (SARS-CoV), que produce el síndrome respiratorio agudo grave3,4. La pandemia debida al virus SARS-CoV-2 requiere de medidas sanitarias urgentes encaminadas a reducir el riesgo de transmisión de la infección3,4. Al momento, no existe tratamiento eficaz para abordar la enfermedad por SARS-CoV-2 (COVID-19). La OMS emitió un informe que los primeros resultados con el uso de Plasma de Convaleciente (CP) puede ser una modalidad de tratamiento potencialmente útil para el COVID-193-5.En este sentido, se señaló la oportunidad de que los Sistemas Transfusionales de cada país realicen una evaluación de riesgos para calibrar su capacidad de extraer, preparar y almacenar este tipo de donaciones. Esto incluye recursos humanos y suministros críticos adecuados, así como un control exhaustivo de procedimientos e infraestructuras. En este marco, se sugiere el inicio de contactos con los servicios hospitalarios para que colaboren en la selección de pacientes, que habiendo superado la enfermedad del COVID-19, pudieran ser candidatos para donación de plasma sin mermar en sus derechos1. La decisión de desarrollar esta opción requiere una revisión rápida, pero exhaustiva, del agente etiológico o agentes relacionados y la respuesta inmune a ellos para evaluar los posibles beneficios y riesgos de la inmunización pasiva. Los principios generales establecidos en los documentos de posición de la Red de Reguladores de Sangre (BRN) de la OMS sobre el uso de plasma convaleciente, como elemento de respuesta a brotes anteriores de virus emergentes (2017) y como respuesta al Coronavirus del Síndrome Respiratorio de Oriente Medio (2014) siguen siendo aplicables también a esta pandemia de SARS-CoV-26,7. La falta de evidencia clínica concluyente del uso del plasma convaleciente en infección por SARS-CoV-2 no debería ser razón para abandonar el uso del plasma convaleciente. Los ensayos clínicos aleatorios están en curso y los resultados no estarán disponibles durante meses en tanto no hay justificación basada en la evidencia disponible y la ética profesional para negar categóricamente el uso del plasma convaleciente en los hospitales que no participan en un ensayo clínico aleatorio. El siguiente protocolo ha tomado algunas de las recomendaciones del Comité Científico para la Seguridad Transfusional del Ministerio de Sanidad de España Versión 1.0 ­ 26 marzo de 20201. Y ha sido modificado para tratar de adaptarlo a la realidad de nuestra institución.


On January 30, 2020, the World Health Organization (WHO) declared that the COVID-19 outbreak constitutes a public health emergency of international concern (PHEIC). On March 11, 2020, the WHO declared the pandemic1,2. COVID-19 is an acute respiratory disease caused by a newly emerging zoonotic coronavirus1. Coronaviruses are a family of viruses that was discovered in the 1960s but whose origin is still unknown. They can cause disease in both animals and humans. In humans, several coronaviruses (229E, OC43, NL63, and HUK 1) are known to be responsible for the common cold, and serious infections of the lower respiratory tract can rarely occur. Two of the coronaviruses cause much more serious and even sometimes fatal infections in humans; These are: MERS-CoV, as the cause of respiratory syndrome in the Middle East, and SARS-CoV, which produces severe acute respiratory syndrome3,4. The pandemic due to the SARS-CoV-2 virus requires urgent sanitary measures aimed at reducing the risk of transmission of the infection3,4. Currently, there is no effective treatment to address SARS-CoV-2 disease (COVID-19). The WHO issued a report that early results with the use of convalescent plasma (PC) may be a potentially useful treatment modality for COVID-193-5. In this sense, the opportunity for the Transfusion Systems of each country to carry out a risk assessment to gauge their ability to extract, prepare and store this type of donation. This includes adequate critical human resources and supplies, as well as a comprehensive control of procedures and infrastructure. In this framework, it is suggested that contacts with hospital services be initiated so that they collaborate in the selection of patients who, having overcome the COVID-19 disease, may be candidates for plasma donation without diminishing their rights1. The decision to develop this option requires a rapid, but comprehensive, review of the etiologic agent or related agents and the immune response to them to assess the possible benefits and risks of passive immunization. The general principles established in the position papers of the WHO Blood Regulators Network (BRN) on the use of convalescent plasma, as an element of response to previous outbreaks of emerging viruses (2017) and as a response to the syndrome coronavirus respiratory problems of the Middle East (2014) are still applicable to this SARS-CoV-2 pandemic6,7. The lack of conclusive clinical evidence of the use of convalescent plasma in SARS-CoV-2 infection should not be a reason to abandon the use of convalescent plasma. Randomized clinical trials are ongoing and results will not be available for months as there is no justification based on available evidence and professional ethics to categorically deny the use of convalescent plasma in hospitals that do not participate in a randomized clinical trial. The following protocol has taken some of the recommendations of the Scientific Committee for Transfusion Safety of the Spanish Ministry of Health Version 1.0 - March 26, 20201. And it has been modified to try to adapt it to the reality of our institution.


Assuntos
Humanos , Masculino , Feminino , Plasma , Pneumonia , Remoção de Componentes Sanguíneos , Doadores de Sangue , Infecções por Coronavirus , Betacoronavirus , Sistema Respiratório , Doenças Respiratórias , Surtos de Doenças , Imunização Passiva , Coronavírus Relacionado à Síndrome Respiratória Aguda Grave , Pandemias
9.
Rev. latinoam. bioét ; 11(2): 106-117, jun.-dic. 2011. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-657071

RESUMO

El tráfico ilegal de especies, si bien es un problema a nivel mundial, para Colombia resulta particularmente grave, si se tiene en cuenta que es el segundo país megadiverso y, por tanto, una buena parte de la vida del Planeta se encuentra sustentada desde el suelo colombiano, es decir, el país es el segundo reservorio genético de la humanidad. Una de las mayores implicaciones de ésta problemática, consiste en la pérdida de la diversidad generada por una fuerte presión hacia la extinción de especies, esto unido al deterioro del hábitat por rupturas en las cadenas tróficas tienen implicaciones que se pueden considerar como catastróficas no sólo a nivel local, sino en un sentido más amplio, a nivel global...


Illegal traffic of species is a well acknowledge International problem. In the of Colombia's It becomes particularly Ernst in that Colombia is the second mega-diverse country. Hence, a large part of life on Earth is placed within the Colombian territory, which makes of this country the second worldwide genetic reservoir for humankind. The most important implications of such a set of problems consist in the loss of diversity generated by the strong pressure on the extinction of species. This is united to the deterioration of the habitat due to the rupture of trophic chains which has serious consequences that can be considered as catastrophic not just on the local level but also in its largest worldwide level...


O tráfico ilegal de espécies, ainda que seja um problema de nível mundial, é particularmente grave para a Colômbia se considerarmos que é o segundo país megadiverso e, portanto, uma boa parte da vida do Planeta se encontra sustentada em solo colombiano, ou seja, o país é o segundo reservatório genético da humanidade. Uma das maiores implicações desta problemática consiste na perda da diversidade, gerada por uma forte pressão para a extinção de espécies. Isto, unido à deterioração do habitat por rupturas nas cadeias tróficas, tem implicações que podem ser consideradas catastróficas não apenas em nível local como, em um sentido mais amplo, em nível global...


Assuntos
Animais , Biodiversidade , Bioética , Conservação dos Recursos Naturais , Ecossistema , Política Ambiental , Conservação dos Recursos Naturais , Ecossistema/prevenção & controle
10.
Rev. colomb. neumol ; 18(3): 123-126, 2006. ilus
Artigo em Espanhol | LILACS | ID: lil-652785

RESUMO

El síndrome de embolismo graso (SEG), es una entidad de difícil diagnóstico y fuente importante de morbilidad y mortalidad en pacientes con fracturas esqueléticas, los síntomas pueden ser enmascarados por condiciones asociadas del paciente, hecho especialmente válido en pacientes politraumatizados. No se ha demostrado una asociación específica entre tipo o ubicación de la fractura y el desarrollo de SEG. El manejo activo de este cuadro, incluyendo soporte ventilatorio, es el factor que se reconoce de mayor importancia en la sobrevida de los pacientes.


Assuntos
Embolia de Colesterol
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA